Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF)

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 1, 1997, Pages 114-121

  Merlos, Manuel ^a   Giral, Marta ^a   Balsa, Dolors ^a   Ferrando, Rosa ^a   Queralt, Mireia ^b   Puigdemont, Anna ^b   García Rafanell, Julián ^a   Forn, Javier ^a,c  

^a Research Center   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Grupo Uriach   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE)PIPERIDINE; ACETYLCHOLINE; ADENOSINE DIPHOSPHATE; ANTIHISTAMINIC AGENT; APAFANT; ARACHIDONIC ACID; BARBITURIC ACID DERIVATIVE; CETIRIZINE; CHLORPHENIRAMINE; CLEMASTINE; DIPHENHYDRAMINE; ESCHERICHIA COLI ENDOTOXIN; GINKGOLIDE B; HISTAMINE; HYDROXYZINE; KETOTIFEN; LEUKOTRIENE D4; LORATADINE; MEPYRAMINE; PENTOBARBITAL; RUPATADINE; SEROTONIN; TERFENADINE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN MEMBRANE; BRONCHOSPASM; CEREBELLUM; CONTROLLED STUDY; DOG; GUINEA PIG; HUMAN; HUMAN TISSUE; HYPOTENSION; ILEUM; INTESTINE CONTRACTION; INTRAVENOUS DRUG ADMINISTRATION; LOCOMOTION; MALE; MORTALITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; SLEEP TIME; THROMBOCYTE AGGREGATION; URTICARIA;

ADMINISTRATION, ORAL; ANIMALS; AZEPINES; BLOOD PRESSURE; CYPROHEPTADINE; DOGS; GUINEA PIGS; HISTAMINE ANTAGONISTS; MALE; MICE; MOTOR ACTIVITY; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; PYRILAMINE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES;

EID: 0030899302     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. ARUNLAKSHANA, O. AND SCHILD, H. O.: Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemotherapy 14: 48-58, 1959.
2. BERTHON, B., TAUDOU, G., COMBETTES, L., CZARLEWSKI, W., CARMI-LEROY, A., MARCHAND, F. AND WEYER, A.: In vitro inhibition, by loratadine and descarboethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3). Biochem, Pharmacol, 47: 789-794, 1994.
3. BILLAH, M. M., CHAPMAN, R. W., EGAN, R. W., GILCHREST, H., PIWINSKI, J. J., SHERWOOD, J., SIEGEL, M. I., WEST, R. E., JR. AND KREUTNER, W.: Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine. J. Pharmacol. Exp. Ther., 252: 1090-1096, 1990.
4. BILLAH, M. M., GILCHREST, H. G., ECKEL, S. P., GRANZOW, C. A., LAWTON, P. J. AND RADWANSKI, E.: Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans. Clin. Pharmacol. Ther. 52: 151-159, 1992.
5. BORN, G. V.: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond.) 194: 927-929, 1962.
6. nd ed., pp. 39.25, Blackwell, Oxford, 1980.
7. BRACKETT, D. J., HAMBURGER, S. A., LERNER, M. R., JONES, S. B., SCHAEFER, C. F., HENRY, D. P. AND WILSON, M. F.: An assessment of plasma histamine concentrations during documented endotoxic shock. Agents Actions 31: 263-274, 1990.
8. BRADFORD, M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
9. CARCELLER, E., MERLOS, M., GIRAL, M., BALSA, D., ALMANSA, C., BARTROLI, J., GARCIA RAFANELL, J. AND FORN, J.: [(3-Pyridylalkyl)piperidylidene]-benzocycloheptapyridine derivatives as dual antagonists of PAF and histamine. J. Med. Chem. 37: 2697-2703, 1994.
10. CARGILL, D. I., COHEN, D. S., VAN VALEN, G. R., KLIMEK, J. J. AND LEVIN, R. P.: Aggregation, release and desensitixation induced in platelets from five species by platelet activating factor (PAF). Thromb. Haemost. 49: 204-207, 1983.
11. CASALS-STENZEL, J., MUACEVIC, G. AND WEBER, K. H.: Pharmacological actions of WEB-2086, a new specific antagonist of platelet-activating factor. J. Pharmacol. Exp. Ther. 241: 974-981, 1987.
12. DEJOY, S. Q., ORONSKY, A. L., WICK, M. M. AND KERWAR, S. S.: Preclinical studies with platelet-activating factor antagonists in models of septic shock. Int. J. Antimicrob. Agents 3: 175-186, 1993.
13. EDA, R., SIGIYAMA, H., HOPP, R. J., BEWTRA, A. K. AND TOWNLEY, R. J.: Effect of loratadine on human eosinophil function in vitro. Ann. Allergy 71: 373-378, 1993.
14. FLOCH, A. AND CAVERO, I.: Influence of plasma protein content and platelet number on the potency of PAF and its antagonist RP 59227 in rabbit platelet preparations. Br. J. Pharmacol. 100: 163-167, 1990.
15. HERBERT, J. M., LESPY, L. AND MAFFRAND, J. P.: Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice. Eur. J. Pharmacol. 205: 271-276, 1991.
16. HOMMA, H., TOKUMURA, A. AND HANAHAN, D. J.: Binding and internalization of platelet-activating factor l-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine in washed platelets. J. Biol. Chem. 262: 10582-10587, 1987.
17. KOLTAI, M., GUINOT, P., HOSFORD, D. AND BRAQUET, P. G.: Platelet-activating factor antagonists: Scientific background and possible clinical applications. Adv, Pharmacol. 28: 81-167, 1994.
18. KONZETT, H. AND RÖSSLER, R.: Versuchsanordnung zu untersuchungen an der bronchialmuskulatur. Arch. Exp. Pathol. Pharmakol. 195: 71-74, 1940.
19. 1 antagonist, astemizole. Mol. Pharmacol. 21: 294-300, 1982.
20. LALAU KERALY, C., DELAUTIER, D., DELABASEE, D., CHIGNARD, M., BENVENISTE, J.: Inhibition by ticlopidine of PAF-acether-induced in vitro aggregation of rabbit and human platelets. Thromb. Res. 34: 463-466, 1984.
21. LEFER, A. M.: Significance of lipid mediators in shock state. Circ. Shock 27: 3-12, 1989.
22. PARRILLO, J. E.: Pathosenetic mechanisms of septic shock. New Engl. J. Med. 328: 1471-1477, 1993.
23. PRETOLANI, M., FERRER-LOPEZ, P. AND VARGAFTIG, B. B.: From anti-asthma drugs to PAF-acether antagonism and back. Present status. Biochem. Pharmacol. 38: 1373-1384, 1989.
24. PRETOLANI, M. AND VARGAFTIG, B. B.: From lung hypersensitivity to bronchial hyperreactivity. What can we learn from studies on animal models? Biochem. Pharmacol. 45: 791-800, 1993.
25. PRESSCOTT, S. M., ZIMMERMAN, G. A. AND MCINTYRE, T. M.: The production of platelet-activating factor by cultured human endothelial cells: Regulation and function. In Platelet-Activating Factor and Related Lipid Mediators, ed. by F. Snyder, F., pp. 323-340, Plenum Press, New York, 1987.
26. 3H]apafant, a selective and competitive platelet-activating factor antagonist: Evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation. Mol. Pharmacol. 43: 302-312, 1992.
27. SANCHEZ-CRESPO, M.: Potential of PAF receptor antagonists in the treatment of septic shock. Drugs News Persp. 6: 78-87, 1993.
28. SCIBERRAS, D. G., BOLOGNESE, J. A., GOLDENBERG, M. M., JAMES, I. AND BABER, N. S.: Platelet-activating factor induced inflammatory responses in the skin. Prostaglandins 35: 833, 1988.
29. 1-receptor antagonist therapy. Clin. Pharmacokin, 21: 372-393, 1991.
30. SNYDER, F.: Metabolic processing of PAF. Clin. Rev. Allergy 12: 309-327, 1994.
31. TALLARIDA, R. J. AND MURRAY, R. B.: Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag, New York, 1981.
32. 1 receptor antagonists for CNS and peripheral receptors? An m vitro study. Eur. J. Pharmacol. 232: 199-205, 1993.
33. TERASHITA, Z. I., IMURA, Y., SHINO, A. AND NISHIKAWA, K.; A lethal role of platelet activating factor in anaphylactic shock in mice. J. Pharmacol. Exp. Ther. 243: 378-383, 1987.
34. 1 effects of second-generation antihistamines. Ann. Allergy 68: 190-196, 1992.
35. WARDLAW, A. J., MOQBEL, R., CROMWELL, O. AND KAY, A. B.: Platelet-activating factor: A potent chemotactic and chemokinetic factor for human eosinophils. J. Clin. Invest. 78: 1701-1706, 1986.
36. WHITE, M. V., SLATER, J. E. AND KALINER, M. A.: Histamine and asthma. Am. Rev. Respir. Dis. 135: 1165-1176, 1987.
37. 1 antihistamine terfenadine: Synthesis and activity. Bioorg, Med. Chem. Lett. 1: 387-390, 1991.